[Interstitial lung disease in connective tissue diseases]

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Context:

• Interstitial lung disease (ILD) is a significant manifestation in rheumatoid arthritis, scleroderma, polymyositis/dermatomyositis, and systemic lupus erythematosus (SLE).
• The presence and progression of ILD significantly impact the overall prognosis and survival rates of patients with these autoimmune conditions.
• Current treatment strategies for ILD in connective tissue diseases are largely guided by expert consensus owing to a scarcity of robust randomized controlled trials.

Purpose:

• To highlight the clinical significance of interstitial lung disease in major connective tissue diseases.
• To emphasize the critical role of early diagnosis in determining patient outcomes.
• To underscore the current limitations in evidence-based treatment due to a lack of randomized controlled trials.

Summary:

• Interstitial lung disease (ILD) is a key clinical feature across rheumatoid arthritis, scleroderma, polymyositis/dermatomyositis, and systemic lupus erythematosus (SLE).
• Early identification of ILD is crucial as it frequently dictates the vital prognosis for affected individuals.
• Treatment decisions for ILD are predominantly based on expert opinion, reflecting the limited availability of randomized controlled trials in this domain.

Impact:

• Improved understanding of ILD as a prognostic determinant in connective tissue diseases.
• Emphasis on the need for early diagnostic strategies for interstitial lung disease.
• Highlights the gap in evidence-based treatment guidelines and the need for further clinical research, particularly randomized controlled trials.